Vectura Group (LON:VEC) had its price objective lowered by Peel Hunt from GBX 160 ($2.21) to GBX 120 ($1.66) in a report released on Wednesday morning. The brokerage currently has a hold rating on the stock.
Several other research analysts also recently commented on the stock. JPMorgan Chase & Co. reissued an overweight rating on shares of Vectura Group in a report on Monday, January 15th. Numis Securities dropped their price objective on shares of Vectura Group from GBX 205 ($2.83) to GBX 170 ($2.35) and set a buy rating for the company in a report on Thursday, November 9th. Royal Bank of Canada raised shares of Vectura Group to a sector performer rating and set a GBX 119 ($1.64) price objective for the company in a report on Thursday, December 14th. Shore Capital reissued a buy rating on shares of Vectura Group in a report on Thursday, November 9th. Finally, Panmure Gordon reissued a buy rating and set a GBX 150 ($2.07) price objective on shares of Vectura Group in a report on Thursday, November 9th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of GBX 169.56 ($2.34).
Vectura Group (LON:VEC) opened at GBX 77.35 ($1.07) on Wednesday. Vectura Group has a 1-year low of GBX 70.50 ($0.97) and a 1-year high of GBX 166.97 ($2.31).
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.